Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin - Université de Lorraine Access content directly
Journal Articles JACC: Heart Failure Year : 2023

Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin

Abstract

BACKGROUND Patients with a recent heart failure (HF) hospitalization have a high risk of rehospitalization and mortality. Early treatment may have a substantial impact on patient outcomes. OBJECTIVES The study sought to study the outcomes and effect of empagliflozin according to timing of prior HF hospitalization. METHODS EMPEROR-Pooled (EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) and EMPEROR-Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction) combined) included 9,718 HF patients who were grouped according to the recency of HF hospitalization (none, <3 months, 3-6 months, 6-12 months, >12 months). The primary outcome was a composite of time to first of HF hospitalization or cardiovascular death, over a median follow-up of 21 months. RESULTS The primary outcome event rates (per 100 person-years) in the placebo group were 26.7, 18.1, 13.7, and 2.8 for patients hospitalized within 3 months, 3-6 months, 6-12 months, and >12 months, respectively. The relative risk reduction of primary outcome events with empagliflozin was similar across HF hospitalization categories (P interaction ¼ 0.67). The primary outcome absolute risk reduction was more pronounced among patients with a recent HF hospitalization but without statistical heterogeneity of treatment effect: À6.9, À5.5, À0.8, and À0.6 events prevented per 100 person-years for patients hospitalized within <3 months, 3-6 months, 6-12 months, and >12 months, respectively, and À2.4 events prevented per 100 person-years of follow-up in those without a prior HF hospitalization (P interaction ¼ 0.64). Empagliflozin was safe irrespective of HF hospitalization recency. CONCLUSIONS Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.
Fichier principal
Vignette du fichier
1-s2.0-S2213177923000732-main.pdf (1.47 Mo) Télécharger le fichier
1-s2.0-S2213177923000732-mmc1.pdf (51.87 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution
Licence : CC BY - Attribution

Dates and versions

hal-04023815 , version 1 (10-03-2023)

Licence

Attribution

Identifiers

Cite

João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filippatos, Stuart Pocock, et al.. Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin. JACC: Heart Failure, 2023, ⟨10.1016/j.jchf.2023.01.018⟩. ⟨hal-04023815⟩
16 View
31 Download

Altmetric

Share

Gmail Facebook X LinkedIn More